Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Senicapoc in Progressive Fibrotic Interstitial Lung Disease
2024-511131-97-00Phase 2Authorised
- Sponsor
- Sygehus Lillebælt
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised trial in progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF) comparing Senicapoc with Placebo (2 arms). Primary endpoint: Rate of decline of FVC (in mL) over 26 weeks. Planned start Aug 2024; status: authorised.
02
Drugs
senicapoc
03
Conditions
progressive pulmonary fibrosis (PPF)idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2024-511131-97-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511131-97-00.